Investment Analysts’ Recent Ratings Updates for Boston Scientific (BSX)

A number of research firms have changed their ratings and price targets for Boston Scientific (NYSE: BSX):

  • 9/7/2018 – Boston Scientific had its “strong-buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $43.00 price target on the stock, up previously from $39.00. They wrote, “BSX announced it is acquiring the private company Augmenix for $500M cash up front and up to $100M in milestones. Augmenix’s SpaceOAR reduces side effects associated with prostate radiotherapy. BSX expects the deal to be immaterial to its adjusted EPS through 2019 and increasingly accretive beginning in 2020. The SpaceOAR hydrogel is CE Marked and FDA cleared and serves an estimated $750M market. We expect the deal to strengthen BSX’s Urology & Pelvic Health business. We expect BSX’s string of acquisitions in 2018 (including Augmenix) to combine to provide a material benefit to its longer-term organic growth and we reiterate our Strong Buy rating and raise our price target to $43 from $39.””
  • 9/5/2018 – Boston Scientific had its price target raised by analysts at Argus to $41.00. They now have a “buy” rating on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 9/4/2018 – Boston Scientific had its price target raised by analysts at Raymond James from $40.00 to $41.00. They now have a “strong-buy” rating on the stock.
  • 9/4/2018 – Boston Scientific was upgraded by analysts at Jefferies Financial Group Inc from a “hold” rating to a “buy” rating. They now have a $42.00 price target on the stock, up previously from $34.00.
  • 7/27/2018 – Boston Scientific had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $43.00 price target on the stock.
  • 7/26/2018 – Boston Scientific had its price target raised by analysts at Morgan Stanley from $33.00 to $38.00. They now have an “overweight” rating on the stock.
  • 7/26/2018 – Boston Scientific had its price target raised by analysts at Piper Jaffray Companies to $38.00. They now have an “overweight” rating on the stock.
  • 7/26/2018 – Boston Scientific had its “hold” rating reaffirmed by analysts at Jefferies Financial Group Inc. They now have a $34.00 price target on the stock.
  • 7/26/2018 – Boston Scientific had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $37.00 price target on the stock.
  • 7/23/2018 – Boston Scientific had its price target raised by analysts at Royal Bank of Canada to $36.00. They now have a “top pick” rating on the stock.
  • 7/23/2018 – Boston Scientific had its price target raised by analysts at SunTrust Banks, Inc. to $39.00. They now have a “buy” rating on the stock.
  • 7/17/2018 – Boston Scientific was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “sell” rating. According to Zacks, “Boston Scientific's delay in the relaunch of the Lotus range of heart devices is expected to hamper sales in 2018 too. We are also concerned about the declining worldwide pacemaker sales hurting Boston Scientific’s CRM business. A competitive market also adds to the woes. However, the company has been gaining from impressive growth across all its business lines and geographies. The 2018 view also paints a bright picture for the near term. Boston Scientific achieved clinical milestones for Ranger Drug Coated Balloon and WATCHMAN Left Atrial Appendage Closure device. Also, post the suspension of Lotus valve in Europe, ACURATE TAVR valve platform continues to build momentum. Lately, the company announced several strategic acquisitions including NxThera and nVision in Urology and Pelvic Health, EmCision in Endoscopy, Securus in EP and Millipede in Structural Heart. Overall, Boston Scientific outperformed its industry in a year’s time.”

NYSE:BSX opened at $37.62 on Friday. The company has a current ratio of 0.83, a quick ratio of 0.60 and a debt-to-equity ratio of 0.62. The firm has a market cap of $49.98 billion, a P/E ratio of 29.86, a price-to-earnings-growth ratio of 2.51 and a beta of 0.63. Boston Scientific Co. has a twelve month low of $24.54 and a twelve month high of $37.72.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 25th. The medical equipment provider reported $0.41 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.34 by $0.07. The business had revenue of $2.49 billion for the quarter, compared to analyst estimates of $2.47 billion. Boston Scientific had a net margin of 5.48% and a return on equity of 26.35%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.32 EPS. sell-side analysts forecast that Boston Scientific Co. will post 1.39 EPS for the current year.

In related news, EVP David A. Pierce sold 5,000 shares of Boston Scientific stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $36.02, for a total transaction of $180,100.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP John Bradley Sorenson sold 10,000 shares of Boston Scientific stock in a transaction on Monday, September 10th. The shares were sold at an average price of $35.86, for a total transaction of $358,600.00. Following the transaction, the senior vice president now owns 44,636 shares in the company, valued at approximately $1,600,646.96. The disclosure for this sale can be found here. Insiders have sold a total of 175,250 shares of company stock worth $6,196,995 in the last 90 days. Company insiders own 0.73% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Quad Cities Investment Group LLC acquired a new position in Boston Scientific in the 2nd quarter worth $104,000. Captrust Financial Advisors lifted its holdings in Boston Scientific by 103.8% in the 2nd quarter. Captrust Financial Advisors now owns 3,129 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 1,594 shares in the last quarter. Kaizen Advisory LLC lifted its holdings in Boston Scientific by 146.7% in the 2nd quarter. Kaizen Advisory LLC now owns 3,299 shares of the medical equipment provider’s stock worth $108,000 after buying an additional 1,962 shares in the last quarter. NumerixS Investment Technologies Inc lifted its holdings in Boston Scientific by 1,650.0% in the 2nd quarter. NumerixS Investment Technologies Inc now owns 3,500 shares of the medical equipment provider’s stock worth $114,000 after buying an additional 3,300 shares in the last quarter. Finally, Sun Life Financial INC lifted its holdings in Boston Scientific by 2,086.5% in the 2nd quarter. Sun Life Financial INC now owns 3,739 shares of the medical equipment provider’s stock worth $122,000 after buying an additional 3,568 shares in the last quarter. Institutional investors and hedge funds own 90.91% of the company’s stock.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

See Also: Dividend

Receive News & Ratings for Boston Scientific Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply